341 related articles for article (PubMed ID: 10991938)
1. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence.
Carroll JS; Prall OW; Musgrove EA; Sutherland RL
J Biol Chem; 2000 Dec; 275(49):38221-9. PubMed ID: 10991938
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
[TBL] [Abstract][Full Text] [Related]
3. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.
Prall OW; Rogan EM; Musgrove EA; Watts CK; Sutherland RL
Mol Cell Biol; 1998 Aug; 18(8):4499-508. PubMed ID: 9671459
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
5. Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(+) tumor cells.
Cheng L; Rossi F; Fang W; Mori T; Cobrinik D
J Biol Chem; 2000 Sep; 275(39):30317-25. PubMed ID: 10906146
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes.
Smith E; Redman RA; Logg CR; Coetzee GA; Kasahara N; Frenkel B
J Biol Chem; 2000 Jun; 275(26):19992-20001. PubMed ID: 10867026
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
8. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1).
Lai A; Sarcevic B; Prall OW; Sutherland RL
J Biol Chem; 2001 Jul; 276(28):25823-33. PubMed ID: 11337496
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest.
Dhillon NK; Mudryj M
Oncogene; 2002 Jul; 21(30):4626-34. PubMed ID: 12096339
[TBL] [Abstract][Full Text] [Related]
11. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes.
Nahum A; Hirsch K; Danilenko M; Watts CK; Prall OW; Levy J; Sharoni Y
Oncogene; 2001 Jun; 20(26):3428-36. PubMed ID: 11423993
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.
Doisneau-Sixou SF; Sergio CM; Carroll JS; Hui R; Musgrove EA; Sutherland RL
Endocr Relat Cancer; 2003 Jun; 10(2):179-86. PubMed ID: 12790780
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
14. Site-directed mutant p21 proteins defective in both inhibition of E2F-regulated transcription and disruption of E2F-p130-cyclin-cdk2 complexes.
Robles SJ; Shiyanov P; Aristodemo GT; Raychaudhuri P; Adami GR
DNA Cell Biol; 1998 Jan; 17(1):9-18. PubMed ID: 9468218
[TBL] [Abstract][Full Text] [Related]
15. The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells.
Tyagi A; Agarwal C; Agarwal R
Cell Cycle; 2002; 1(2):137-42. PubMed ID: 12429923
[TBL] [Abstract][Full Text] [Related]
16. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
Hui R; Finney GL; Carroll JS; Lee CS; Musgrove EA; Sutherland RL
Cancer Res; 2002 Dec; 62(23):6916-23. PubMed ID: 12460907
[TBL] [Abstract][Full Text] [Related]
17. E2F/p107 and E2F/p130 complexes are regulated by C/EBPalpha in 3T3-L1 adipocytes.
Timchenko NA; Wilde M; Iakova P; Albrecht JH; Darlington GJ
Nucleic Acids Res; 1999 Sep; 27(17):3621-30. PubMed ID: 10446255
[TBL] [Abstract][Full Text] [Related]
18. G1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression.
Calbó J; Parreño M; Sotillo E; Yong T; Mazo A; Garriga J; Grana X
J Biol Chem; 2002 Dec; 277(52):50263-74. PubMed ID: 12401786
[TBL] [Abstract][Full Text] [Related]
19. CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells.
Lee AW; Nambirajan S; Moffat JG
Oncogene; 1999 Dec; 18(52):7477-94. PubMed ID: 10602507
[TBL] [Abstract][Full Text] [Related]
20. A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2.
Prall OW; Carroll JS; Sutherland RL
J Biol Chem; 2001 Nov; 276(48):45433-42. PubMed ID: 11581254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
